Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus.

Yu HoshikaYoshiaki KubotaKosuke MozawaShuhei TaraYukichi TokitaKenji YodogawaYu-Ki IwasakiTakeshi YamamotoHitoshi TakanoYayoi TsukadaKuniya AsaiMasaaki MiyamotoYasushi MiyauchiEitaro KodaniMitsunori MaruyamaJun TanabeWataru Shimizu

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)

UMIN 000030158.

Keyphrases

acute myocardial infarction
percutaneous coronary intervention
left ventricular
glycemic control
double blind
phase iii
cardiovascular risk factors
heart failure
type diabetes
clinical trial
metabolic syndrome
skeletal muscle
placebo controlled
weight loss
open label